Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1250 of 2529 entries
View as:

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Phase: N/A Priority: Normal
NCT ID: NCT06133972 Org: User:
Start: 05/21/24 End: 12/23/31 Due: 12/23/32

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Phase: N/A Priority: Normal
NCT ID: NCT05622708 Org: User:
Start: 03/28/23 End: 06/21/30 Due: 06/21/31

Secukinumab Open Label Roll-over Extension Protocol

Phase: N/A Priority: Normal
NCT ID: NCT04638647 Org: User:
Start: 12/22/20 End: 04/04/30 Due: 04/04/31

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Phase: N/A Priority: Normal
NCT ID: NCT05624749 Org: User:
Start: 04/21/23 End: 04/20/29 Due: 04/20/30

Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).

Phase: N/A Priority: Normal
NCT ID: NCT04230148 Org: User:
Start: 02/11/22 End: 12/10/26 Due: 12/10/27

A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Phase: N/A Priority: Normal
NCT ID: NCT05985915 Org: User:
Start: 10/27/23 End: 07/18/30 Due: 07/18/31

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Phase: N/A Priority: Normal
NCT ID: NCT04023552 Org: User:
Start: 12/12/19 End: 02/26/26 Due: 02/26/27

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Phase: N/A Priority: Normal
NCT ID: NCT05767034 Org: User:
Start: 03/22/23 End: 02/17/26 Due: 02/17/27

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Phase: N/A Priority: Normal
NCT ID: NCT06267560 Org: User:
Start: 04/24/24 End: 03/11/27 Due: 03/11/28

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Phase: N/A Priority: Normal
NCT ID: NCT06869785 Org: User:
Start: 03/13/25 End: 05/26/31 Due: 05/26/32

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

Phase: N/A Priority: Normal
NCT ID: NCT06632600 Org: User:
Start: 04/28/25 End: 11/05/27 Due: 11/05/28

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Phase: N/A Priority: Normal
NCT ID: NCT06335979 Org: User:
Start: 10/08/24 End: 07/09/27 Due: 07/09/28

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Phase: N/A Priority: Normal
NCT ID: NCT06331312 Org: User:
Start: 06/28/24 End: 02/10/28 Due: 02/10/29

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Phase: N/A Priority: Normal
NCT ID: NCT05639114 Org: User:
Start: 03/02/23 End: 04/20/29 Due: 04/20/30

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Phase: N/A Priority: Normal
NCT ID: NCT06675864 Org: User:
Start: 12/12/24 End: 06/13/30 Due: 06/13/31

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Phase: N/A Priority: Normal
NCT ID: NCT06733922 Org: User:
Start: 11/27/24 End: 11/30/27 Due: 11/30/28

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Phase: N/A Priority: Normal
NCT ID: NCT00449761 Org: User:
Start: 02/23/07 End: 08/26/08 Due: 08/26/09

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT04926818 Org: User:
Start: 10/05/21 End: 11/18/31 Due: 11/18/32

Iptacopan in Patients With ANCA Associated Vasculitis

Phase: N/A Priority: Normal
NCT ID: NCT06388941 Org: User:
Start: 08/05/24 End: 10/05/27 Due: 10/05/28

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

Phase: N/A Priority: Normal
NCT ID: NCT00396357 Org: User:
Start: 10/31/06 End: - Due: -

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT06655896 Org: User:
Start: 10/29/24 End: 10/13/32 Due: 10/13/33

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Phase: N/A Priority: Normal
NCT ID: NCT05677451 Org: User:
Start: 07/11/23 End: 03/30/32 Due: 03/30/33

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT06744920 Org: User:
Start: 02/07/25 End: 02/26/33 Due: 02/26/34

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01646684 Org: User:
Start: 03/08/13 End: 11/13/18 Due: 11/13/19

Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.

Phase: N/A Priority: Normal
NCT ID: NCT03989635 Org: User:
Start: 10/15/19 End: 06/14/21 Due: 06/14/22